JP2017512194A5 - - Google Patents

Download PDF

Info

Publication number
JP2017512194A5
JP2017512194A5 JP2016553329A JP2016553329A JP2017512194A5 JP 2017512194 A5 JP2017512194 A5 JP 2017512194A5 JP 2016553329 A JP2016553329 A JP 2016553329A JP 2016553329 A JP2016553329 A JP 2016553329A JP 2017512194 A5 JP2017512194 A5 JP 2017512194A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
administered
fgf
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016553329A
Other languages
English (en)
Japanese (ja)
Other versions
JP6431083B2 (ja
JP2017512194A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/053624 external-priority patent/WO2015124727A1/en
Publication of JP2017512194A publication Critical patent/JP2017512194A/ja
Publication of JP2017512194A5 publication Critical patent/JP2017512194A5/ja
Application granted granted Critical
Publication of JP6431083B2 publication Critical patent/JP6431083B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016553329A 2014-02-20 2015-02-20 Fgf−18化合物の投与計画 Active JP6431083B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14000600 2014-02-20
EP14000600.8 2014-02-20
PCT/EP2015/053624 WO2015124727A1 (en) 2014-02-20 2015-02-20 Fgf-18 compound dosing regimen

Publications (3)

Publication Number Publication Date
JP2017512194A JP2017512194A (ja) 2017-05-18
JP2017512194A5 true JP2017512194A5 (cg-RX-API-DMAC10.html) 2018-03-08
JP6431083B2 JP6431083B2 (ja) 2018-11-28

Family

ID=50151088

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016553284A Active JP6431082B2 (ja) 2014-02-20 2015-02-20 Fgf−18化合物の投与計画
JP2016553329A Active JP6431083B2 (ja) 2014-02-20 2015-02-20 Fgf−18化合物の投与計画

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016553284A Active JP6431082B2 (ja) 2014-02-20 2015-02-20 Fgf−18化合物の投与計画

Country Status (25)

Country Link
US (2) US9724388B2 (cg-RX-API-DMAC10.html)
EP (2) EP3119417B1 (cg-RX-API-DMAC10.html)
JP (2) JP6431082B2 (cg-RX-API-DMAC10.html)
KR (2) KR102410988B1 (cg-RX-API-DMAC10.html)
CN (2) CN106232622A (cg-RX-API-DMAC10.html)
AR (2) AR099510A1 (cg-RX-API-DMAC10.html)
AU (2) AU2015220773B2 (cg-RX-API-DMAC10.html)
BR (2) BR112016018696A2 (cg-RX-API-DMAC10.html)
CA (2) CA2938793A1 (cg-RX-API-DMAC10.html)
DK (2) DK3119417T3 (cg-RX-API-DMAC10.html)
ES (2) ES2688551T3 (cg-RX-API-DMAC10.html)
HR (2) HRP20181570T1 (cg-RX-API-DMAC10.html)
HU (1) HUE040350T2 (cg-RX-API-DMAC10.html)
IL (2) IL247083B (cg-RX-API-DMAC10.html)
LT (2) LT3107559T (cg-RX-API-DMAC10.html)
MX (2) MX2016010872A (cg-RX-API-DMAC10.html)
NZ (1) NZ723148A (cg-RX-API-DMAC10.html)
PL (2) PL3119417T3 (cg-RX-API-DMAC10.html)
PT (2) PT3119417T (cg-RX-API-DMAC10.html)
RS (2) RS57853B1 (cg-RX-API-DMAC10.html)
RU (2) RU2691946C2 (cg-RX-API-DMAC10.html)
SG (2) SG11201606502YA (cg-RX-API-DMAC10.html)
SI (2) SI3119417T1 (cg-RX-API-DMAC10.html)
WO (2) WO2015124731A1 (cg-RX-API-DMAC10.html)
ZA (2) ZA201605548B (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ723177A (en) 2014-02-20 2021-12-24 Merck Patent Gmbh Implant comprising fgf-18
BR112016018696A2 (pt) 2014-02-20 2017-10-17 Merck Patent Gmbh regime de dosagem com composto de fgf-18
JP6787904B2 (ja) 2015-01-29 2020-11-18 アレス トレーディング ソシエテ アノニム 高度に正に荷電したタンパク質のイムノアッセイ
RU2743075C2 (ru) 2016-02-22 2021-02-15 Новартис Аг Способы применения агонистов fxr
US11467169B2 (en) * 2017-09-29 2022-10-11 Merck Patent Gmbh Inflammatory biomarkers for predicting responsiveness to FGF-18 compound
US11513128B2 (en) 2017-09-29 2022-11-29 Merck Patent Gmbh Metabolic biomarkers for predicting responsiveness to FGF-18 compound
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial
WO2020161341A1 (en) * 2019-02-08 2020-08-13 Merck Patent Gmbh Treatment of patients at risk of rapid progression of osteoarthritis
WO2025077768A1 (en) * 2023-10-11 2025-04-17 Sichuan Real & Best Biotech Co., Ltd. Compositions and methods for treating arthritis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136970A1 (en) * 2002-10-07 2004-07-15 Ellsworth Jeff L. Methods for administering FGF18
ES2706848T3 (es) * 2004-07-06 2019-04-01 Zymogenetics Inc Composición farmacéutica que comprende FGF18 y antagonista de IL-1 y método de uso
AU2006326870A1 (en) * 2005-12-22 2007-06-28 Apollo Life Sciences Transdermal delivery of pharmaceutical agents
CA2658511C (en) * 2006-08-25 2019-02-19 Ares Trading S.A. Use of fgf-18 compound to treat cartilage disorders
BRPI0715728A8 (pt) * 2006-08-25 2018-04-03 Ares Trading Sa tratamento de distúrbios cartilaginosos
DE102006043260A1 (de) * 2006-09-11 2008-03-27 Krones Ag Etikettieranlage
WO2012127506A1 (en) * 2011-03-22 2012-09-27 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
NZ723177A (en) 2014-02-20 2021-12-24 Merck Patent Gmbh Implant comprising fgf-18
WO2015124735A1 (en) 2014-02-20 2015-08-27 Merck Patent Gmbh Fgf-18 in graft transplantation and tissue engineering procedures
BR112016018696A2 (pt) 2014-02-20 2017-10-17 Merck Patent Gmbh regime de dosagem com composto de fgf-18

Similar Documents

Publication Publication Date Title
JP2017512194A5 (cg-RX-API-DMAC10.html)
JP2017507142A5 (cg-RX-API-DMAC10.html)
JP2012193216A5 (cg-RX-API-DMAC10.html)
JP2015517488A5 (cg-RX-API-DMAC10.html)
JP2015038135A5 (cg-RX-API-DMAC10.html)
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
JP2015057451A5 (cg-RX-API-DMAC10.html)
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
FI3936130T3 (fi) Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon
JP2016530280A5 (cg-RX-API-DMAC10.html)
HRP20230300T1 (hr) Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije
MX2016010179A (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
RU2016137289A (ru) Схема применения соединения fgf-18
WO2015171965A3 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
JP2013541583A5 (cg-RX-API-DMAC10.html)
JP2017501140A5 (cg-RX-API-DMAC10.html)
JP2017503014A5 (cg-RX-API-DMAC10.html)
JP2016505050A5 (cg-RX-API-DMAC10.html)
JP2016512247A5 (cg-RX-API-DMAC10.html)
JP2018506533A5 (cg-RX-API-DMAC10.html)
JP2021505669A5 (cg-RX-API-DMAC10.html)
JP2019529569A5 (cg-RX-API-DMAC10.html)
JP2017531042A5 (cg-RX-API-DMAC10.html)
HRP20161796T1 (hr) Farmaceutski pripravak za primjenu u tretmanu ili prevenciji deficijencije vitamina i minerala kod pacijenata podvrgnutih operaciji želučane premosnice
EP4282485A3 (en) Dosage regimen for pegylated interferon